Quarterly report · Q2
4544.TEDINET S100PJXC
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥134.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥133.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥17.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥27.0bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥17.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.7bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥20.7bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥25.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥19.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥19.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥285.9bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥271.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥128.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥157.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥130.9bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥37.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥37.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥41.8bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥15.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥20.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥18.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥273.42 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.17 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥342.23 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.93 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥273.38 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥342.1 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 55.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥85.1bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥85.0bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥83m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥40.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥15.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥604m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥139.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥134.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥19.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥4.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥4.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥746m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥88.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥88.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥33m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥138.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥133.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.9bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥27.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 532
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ca | Prior1YearInstant | 8003000000 | JPY |
| Other ca | CurrentQuarterInstant | 7845000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -675000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -460000000 | JPY |
| Current assets | Prior1YearInstant | 132542000000 | JPY |
| Current assets | CurrentQuarterInstant | 120052000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 21227000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 23918000000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant | 14777000000 | JPY |
| Tools furniture and fixtures net | CurrentQuarterInstant | 17295000000 | JPY |
| Land | Prior1YearInstant | 10488000000 | JPY |
| Land | CurrentQuarterInstant | 10638000000 | JPY |
| Other net ppe | Prior1YearInstant | 30026000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 27196000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 76520000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 79049000000 | JPY |
| Goodwill | Prior1YearInstant | 201000000 | JPY |
| Goodwill | CurrentQuarterInstant | 9478000000 | JPY |
| Customer related intangible assets ia | Prior1YearInstant | 897000000 | JPY |
| Customer related intangible assets ia | CurrentQuarterInstant | 889000000 | JPY |
| Software | Prior1YearInstant | 22250000000 | JPY |
| Software | CurrentQuarterInstant | 21106000000 | JPY |
| Other ia | Prior1YearInstant | 11057000000 | JPY |
| Other ia | CurrentQuarterInstant | 12916000000 | JPY |
| Intangible assets | Prior1YearInstant | 34406000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 44390000000 | JPY |
| Investment securities | Prior1YearInstant | 8300000000 | JPY |
| Investment securities | CurrentQuarterInstant | 8887000000 | JPY |
| Other ioa | Prior1YearInstant | 34861000000 | JPY |
| Other ioa | CurrentQuarterInstant | 33778000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -165000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -332000000 | JPY |
| Investments and other assets | Prior1YearInstant | 42996000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 42333000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 153923000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 165772000000 | JPY |
| Deferred assets | Prior1YearInstant | 121000000 | JPY |
| Deferred assets | CurrentQuarterInstant | 108000000 | JPY |
| Assets | Prior1YearInstant | 286587000000 | JPY |
| Assets | CurrentQuarterInstant | 285933000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 21307000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 19553000000 | JPY |
| Electronically recorded obligations operating cl | Prior1YearInstant | 1025000000 | JPY |
| Electronically recorded obligations operating cl | CurrentQuarterInstant | 1032000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 3621000000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | 5510000000 | JPY |
| Accounts payable other | Prior1YearInstant | 14921000000 | JPY |
| Accounts payable other | CurrentQuarterInstant | 11473000000 | JPY |
| Income taxes payable | Prior1YearInstant | 5834000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 2549000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |